Retinitis Pigmentosa Market

Retinitis Pigmentosa Market size was valued at USD 15.16 Bn in 2025 and is expected to reach USD 25.64 Bn by 2032, at a CAGR of 7.8%.

Overview

Retinitis Pigmentosa (RP) is a series of eye problems that affect the retina. It is a genetic condition and passed down in families. Retinitis Pigmentosa is measured and diagnosed by genetic testing, electroretinography, visual field testing and optical coherence tomography. Retinitis Pigmentosa is a series of vision disorders that affects about 1 in 3000 to 1 in 4000 people in the world. The report includes historical data, present and future trends, competitive environment of the Retinitis Pigmentosa industry. The bottom-up approach was used to estimate the Retinitis Pigmentosa market size. The market revenue is determined by the primary and secondary data collection methods.

To know about the Research Methodology :- Request Free Sample Report

Retinitis Pigmentosa Market Dynamics

Increasing prevalence of Retinitis Pigmentosa to fuel the market growth

The increasing number of gene mutations and inherited disorders in the eye, leads to increase the risk of Retinitis Pigmentosa. It is a common disease that causes functional visual problems in young adults. Retinitis Pigmentosa is caused due to a genetic defect in the genes responsible for the proper function of the visual cycle which resulted in the loss of function of photoreceptors and abnormal protein formation. An increase in relative marriage has been another factor that responsible to rise the number of Retinitis Pigmentosa patients. Since the increasing prevalence of Retinitis Pigmentosa boosts the Retinitis Pigmentosa market growth.

Growing investment in the healthcare infrastructure to fuel the market demand

Public and private organizations have been increasing initiatives and investments in the healthcare sector to expand awareness about Retinitis Pigmentosa. The rising disposable income and increasing demand for disease novel treatment help to influence the market. In the diagnostic process of Retinitis Pigmentosa, the psychological aspects have been considered such as shock, fear, panic and a lack of confidence. As a result, in the diagnostic process of Retinitis Pigmentosa healthcare providers have been increasing their investment to introduce advanced treatments and manage available treatments without giving psychological shocks. Thus, rising investment in the healthcare infrastructure fuel the Retinitis Pigmentosa Market.

Retinitis Pigmentosa Market Opportunity: Rising number of research and development activitiesThe increasing approvals as well as launches of the new Retinitis Pigmentosa drugs, rising investment in the development of the new and advanced technologies and growth of the emerging markets are the upcoming lucrative opportunities for the growth of the Retinitis Pigmentosa industry.

Retinitis Pigmentosa Market Restraints: The availability of limited treatment options for Retinitis Pigmentosa and the need for skilled professionals are the factors responsible to restrain the market growth. The lack of healthcare infrastructure in developing economies also negatively affects market growth. On the other hand, family history and the increasing number of relative marriages hampers the growth of the Retinitis Pigmentosa market.

Asia Pacific is expected to grow with a significant CAGR for the Retinitis Pigmentosa Market during the forecast period. The adoption of advanced technologies, the existence of the geriatric population, the rising healthcare infrastructure and the presence of a large population base which are suffering from eye disease. In the Asia Pacific, the government and private organizations are funding treatment costs, which makes people prefer the treatment. All the factors contributing to the regional Retinitis Pigmentosa Market growth.

Retinitis Pigmentosa Market Segmentation

By Type

Based on the Type, the market is categorized as Autosomal Recessive, Autosomal Dominant and X-Linked. Autosomal Recessive held the largest revenue in 2025and is expected to grow rapidly for the Retinitis Pigmentosa Market. Autosomal Recessive diseases are more common than Autosomal Dominant and X-Linked. 35 genes have been associated with the autosomal recessive form of the disorder. Between the ages of 25 and 40, the Autosomal Recessive develops pre-emptively. Autosomal recessive disorder needs two copies of the mutated gene to cause the disorder and spread rapidly among the younger generation. The presence of Autosomal Recessive diseases in a family is passed down in one child or in siblings. As a result, Autosomal Recessive Retinitis Pigmentosa dominates the market.

By Treatment

On the basis of the treatment, the market is divided into Vitamin A, Docosahexaenoic acid (DHA), Calcium channel blockers, Gene therapy, Retinal eye prosthetics and others. In 2025, Vitamin A dominated the Retinitis Pigmentosa market and is expected to continue its dominance over the forecast period. There are does not have standard treatments for the patient, which suffer from Retinitis Pigmentosa disorder. Supplementation with vitamin A is the widely accepted treatment for Retinitis Pigmentosa. The Vitamin A supplementation accelerates lipofuscin accumulation in the retinal pigment epithelium of a mouse model to inherited ABCA4-medicated retinal dystrophies. The patients are supplemented with a high vitamin A dose and also monitor for liver function tests.

By Route of Administration

Based on the Route of Administration, the market is categorized into oral, topical and others. The oral route of administration had the largest revenue in 2025. The oral administration route is more effective in reducing central muscular thickness and improving visual acuity (VA) in RP-CME patients. Oral is safe and tolerated by patients with advanced Retinitis Pigmentosa and improves the function of the muscular cones. The oral administration promoted tedious cone survival and support to maintain cone electroretinographic function.

By Diagnosis

On the basis of the Diagnosis, the market is segmented into Electroretinogram, Visual Field Testing, Genetic Testing and Others. In 2025, the Electroretinogram segment lead the market with the largest revenue share and is expected to continue its dominance over the forecast period. The Electroretinogram diagnosis is the essential diagnosis of the Retinitis Pigmentosa and it measures the electrical potential produced by the cones and rods after light stimulus.

The Electroretinogram test significantly evaluated the disorders of the retina and help to determine the retinal surgery. This diagnosis test appears in the normal way when the retina is slightly affected, thus the maximum Electroretinogram amplitude decreases. Thus Electroretinogram diagnosis is a more effective diagnosis method rather than others.

By End-Users

On the basis of the End-Users, the market is categorized into Hospitals, Specialty Clinics, Homecare, ophthalmologist and others. The hospital’s segment is significantly dominated the retinitis pigmentosa market. The increasing prevalence of retinitis pigmentosa pushed patients to enter the hospitals for the treatment of eye disorders. A more advanced diagnosis process is available in hospitals and provides better treatment for retinitis pigmentosa.

By Distribution Channel

Based on the Distribution Channel, the market is divided into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. The hospital pharmacy held the market in 2025 and is expected to grow significantly for the market. The segment is driven by the increase in the demand for treatment–based drugs for the retinitis pigmentosa and the growing number of patients suffering from eye retina disorders.

Retinitis Pigmentosa Market Regional Insights

North America dominated the Retinitis Pigmentosa Market in 2025 and is expected to maintain its dominance during the forecast period. The presence of the key players and well-developed healthcare infrastructure increasing the number the research and development activities are the growth contributors to the regional market. The growing cases of arrhythmic diseases, changing lifestyles of the people, increasing demand for advanced treatment methods, and favorable reimbursement policies for patients are also influencing factors that help to boost the regional Retinitis Pigmentosa industry growth.

The United States is dominating the regional Retinitis Pigmentosa market in terms of value and volume. In the US, with the increasing prevalence of retina disorders, people always give preference for the diagnosis process of Retinitis Pigmentosa.

Competitive Landscape

The information on the competitive environment such as market share and positioning of key players is included in the market report. Some of the key players are adopted strategies including pricing investments, expansion of the product portfolio, mergers and acquisition collaboration, agreements and geographical expansion for the enhancement of the Retinitis Pigmentosa industry. The companies are investing in research and development activities regarding Retinitis Pigmentosa.
For example: MeiraGTx Limited (US)

Recently, This Company has six programs in clinical development such as phase 1/2 clinical-stage programs in Achromatopsia (ACHM), X-Linked Retinitis Pigmentosa (XLRP) and RPE65-Deficiency, two phases 1 clinical trial for radiation-induced xerostomia(RIX) and a Parkinson’s program that has been completed a phase 2 trial with published data.

Retinitis Pigmentosa Market Scope: Inquire before buying

Retinitis Pigmentosa Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key Players/Competitors Profiles Covered in the Retinitis Pigmentosa Market Report in a Strategic Perspective

1. Bausch Health Companies Inc. (Canada)
2.MeiraGTx Limited (US)
3.Novartis AG(Switzerland)
4.Sun Pharmaceutical Industries Ltd. (India)
5.Allergan (Ireland)
6.Astellas Pharma Inc. (Japan)
7.AstraZeneca (UK)
8.Johnson & Johnson Private Limited (US)
9.Orphagen Pharmaceuticals, Inc (US)
10.Clino Corporation (Japan)
11.Spark Therapeutics, Inc (US)
12.Caladrius Biosciences, Inc. (US)
13.Genethon (France)
14.Gensight Biologics(France)
15.Grupo Ferrer International, S.A. (Spain)
16.Nanovector S.r.l (Italy)
17.Mimetogen Pharmaceuticals Inc. (Canada)
18.Ionis Pharmaceuticals, Inc. (US)
19.AGTC (US)
20.ReNeuron Group plc (UK)
21.ProQR Therapeutics. (Netherlands)

Frequently Asked Questions:

1] What is the growth rate of the Global Retinitis Pigmentosa Market?
Ans. The Global Retinitis Pigmentosa Market is growing at a significant rate of 7.8 % during the forecast period.

2] Which region is expected to dominate the Global Retinitis Pigmentosa Market?
Ans. North America is expected to dominate the Retinitis Pigmentosa Market during the forecast period.

3] What is the expected Global Retinitis Pigmentosa Market size by 2032?
Ans. The Retinitis Pigmentosa Market size is expected to reach USD 25.64 Bn by 2032.

4] Which are the top players in the Global Retinitis Pigmentosa Market?
Ans. The major top players in the Global Retinitis Pigmentosa Market are Bausch Health Companies Inc. (Canada), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Allergan (Ireland), Astellas Pharma Inc. (Japan), AstraZeneca (UK) and others.

5] What are the factors driving the Global Retinitis Pigmentosa Market growth?
Ans. The increasing prevalence of Retinitis Pigmentosa and growing investment in the healthcare infrastructure are expected to drive market growth during the forecast period.